The affordability of prescription medicines in Australia: Are copayments and safety net thresholds too high?

Australian Health Review

Volumn 37, Issue 1, 2013, Pages 32-40

  Searles, Andrew ^a   Doran, Evan ^b   Faunce, Thomas A ^c   Henry, David ^b,d  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c The Australian National University   (Australia)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874251090     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH11153     Document Type: Article

References (39)

1. Department of Health and Ageing. National Medicines Policy. 2000; Available at http://www.tga.gov.au/docs/html/advreg.htm [verified 11 October 2011].
2. Sweeny K. Key aspects of the Australian Pharmaceutical Benefits Scheme, Working paper. Melbourne: Centre for Strategic Economic Studies, Victoria University of Technology; 2007.
3. McManus P, Mant A, Birkett D, Hemming M, Lindner J. Examining the adequacy of quantities available for subsidised antidepressant prescriptions in Australia. Pharmacoepidemiol Drug Saf 1999; 8: 191-5. doi:10.1002/(SICI)1099- 1557(199905/06)8:3<191::AID-PDS417>3.0. CO;2-X 4 Australian Institute of Health and Welfare. Health expenditure Australia 2009-10. Canberra: AIHW; 2011.
4. Doran E, Robertson J, Rolfe I, Henry D. Patient co-payments and use of prescription medicines. Aust N Z J Public Health 2004; 28(1): 62-7. doi:10.1111/j.1467-842X.2004.tb00634.x\\
5. Doran E, Roberston J. Australia's pharmaceutical cost sharing policy: reducing waste or affordability? Aust Health Rev 2009; 33(2): 231-40. doi:10.1071/AH090231
6. Joyce GF, Escarce JJ, SolomonMD,GoldmanDP. Employer drug benefit plans and spending on prescription drugs. JAMA 2002; 288(14): 1733-9. doi:10.1001/jama.288.14.1733
7. Hsu J, Price M, Huang J, Brand R, Fung V, Hui R, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006; 354(22): 2349-59. doi:10.1056/NEJMsa054436
8. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001; 285(4): 421-9. doi:10.1001/jama.285.4.421
9. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy Benefits and the use of drugs by the chronically ill. JAMA 2004; 291(19): 2344-50. doi:10.1001/jama.291.19.2344
10. Choice. PBS reform. 2009. Available at http://www.choice.com.au/consumer- action/past-campaigns/health/pbs-reform.aspx [verified 9 October 2012].
11. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability: An international comparison of chronic disease medicines. Cairo: World Health Organization; 2006.
12. Hunter Valley Research Foundation. Wellbeing Watch. Newcastle: Hunter Valley Research Foundation; 2006.
13. Blendon RJ, Schoen C, DesRoches CM, Osborn R, Scoles KL, Zapert K. Inequities in health care: A five-country survey. Health Aff 2002; 21(3): 182-91. doi:10.1377/hlthaff.21.3.182
14. Schoen C, Osborn R, Huynh PT, Doty M, Zapert K, Peugh J, et al. Taking the pulse of health care systems: Experiences of patients with health problems in six countries. Health Aff 2005; 24: 509-25.
15. Davis K, Schoen C, Schoenbaum SC, DotyMM,Holmgren AL, Kriss JL, et al. Mirror, mirror on the wall: An international update on the comparative performance of American health care. New York: Commonwealth Fund; 2007. Available from http://www.commonwealthfund.org/Publications/Fund-Reports/2007/ May/Mirror-Mirror-on-the-Wall-An-International-Update-on-the-Comparative- Performance-of-American-Healt.aspx#citation [Verified 9 October 2012].
16. Department of Health and Ageing. About the PBS. Canberra: Department of Health and Ageing; 2012. Available at http://www.pbs.gov.au/info/about-the-pbs [verified 9 October 2012].
17. Medicare Australia.PBSSafety Net. Canberra: Department of Health and Ageing; 2012. Available at http://www.medicareaustralia.gov.au/provider/pbs/ pharmacists/safety-net.jsp [verified 9 October 2012].
18. Hunter Valley Research Foundation. Wellbeing Watch. Newcastle: Hunter Valley Research Foundation; 2008. Available at http://www. hvrf.com.au/pages/ publications/index.php [verified 23 February 2009].
19. Australian Bureau of Statistics. 2006 Census. Available at http://www. censusdata.abs.gov.au/ABSNavigation/prenav/PopularAreas?Read Form&prenavtabname=Popular%20Locations&type=popular&&nav mapdisplayed=true&javascript=true&textversion=false&collection= Census&period=2006&producttype=Community%20Profiles& method=&productlabel=&breadcrumb=PL&topic=&. [verified 2 June 2012]
20. Australian Bureau of Statistics. Monthly Labour Force Survey, 2012.Available at http://www.abs.gov.au/ausstats/abs@nsf/PrimaryMain Features/6291.0.55.001?OpenDocument [Verified 9 October 2012].
21. Health Action International, World Health Organization. Medicine prices, availability and affordability in Jordan. 2007. Available at http://www.haiweb.org/medicineprices/surveys/200405JO/survey-report.pdf [Verified 9 October 2012].
22. Anvarova J, Maqsudova N, Haknazarova M, Isupov S, Jafarov A, Abdulazizov S, et al. Medicine prices in the Republic of Tajikistan: Survey report February 2005. Available at http://www.haiweb.org/medicineprices/surveys/200502TJ/survey- report.pdf [Verified 9 October 2012].
23. Babar Z-U-D, Ibrahim MIM, Singh H, Bukhari NI.Asurvey of medicine prices, availability, affordability and price components in Malaysia using the HAI/WHO methodology: University College Sedaya International and University Sains Malaysian in collaboration with the World Health Organisation and Health Action International 2005. Available at http://www.haiweb.org/medicineprices/surveys/ 200410MY/survey-report. pdf [Verified 9 October 2012].
24. Ball D, Tisocki K, Al-Saffar N. Medicine prices in the State of Kuwait: report of a survey on medicine prices in Kuwait. Kuwait; 2005. Available at http://www.haiweb.org/medicineprices/surveys/200406KW/survey- report.pdf [Verified 9 October 2012].
25. Rahimi AR, Spertus JA, Reid KJ, Bernheim SM, Krumholz HM. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA 2007; 297(10): 1063-72. doi:10.1001/jama.297.10.1063
26. Reed M, Brand R, Newhouse JP, Selby JV, Hsu J. Coping with prescription drug cost sharing: knowledge, adherence, and financial burden. Health Serv Res 2008; 43(2): 785-97. doi:10.1111/j.1475-6773.2007.00797.x\\
27. Rogowski J, Lillard LA, Kington R. The financial burden of prescription drug use among elderly persons. Gerontologist 1997; 37(4): 475-82. doi:10.1093/geront/37.4.475
28. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011; 12(10): 933-80. doi:10.1016/S1470-2045(11)70141-3
29. Robotham J. Huge increase in the use of prescription drugs among over 50. Sydney Morning Herald. 16 January 2012. Available at http://www. smh.com.au/national/health/huge-increase-in-the-use-of-prescriptiondrugs-among- those-over-50-20120115-1q1fj.html [verified 9 October 2012].
30. Morgan TK, WilliamsonM,PirottaM,Stewart K, Meyers SP, Barnes J.A national census of medicines use: A 24-hour snapshot of Australians aged 50 years and older. Med J Aust 2012; 196(1): 50-3. doi:10.5694/mja11. 10698
31. Kemp A, Roughead E, Preen D, Glover J, Semmens J. Determinants of self-reported medicine underuse due to cost: A comparison of seven countries. J Health Serv Res Policy 2010; 15(2): 106-14. doi:10.1258/jhsrp.2009.009059
32. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 2008; 17(11): 1091-9. doi:10.1002/pds.1670
33. Jan S, Essue BM, Leeder SR. Falling through the cracks: The hidden economic burden of chronic illness and disability on Australian households. Med J Aust 2012; 196(1): 29-31. doi:10.5694/mja11.11105
34. Essue B, Kelly P, Roberts M, Leeder S, Jan S.Wecan't affordmychronic illness! The out-of pocket burden associated with managing chronic obstructive pulmonary disease in western Sydney, Australia. J Health Serv Res Policy 2011; 16(4): 226-31. doi:10.1258/jhsrp.2011.010159
35. Lehnbom EC, Boxall A, Russell LM, Brien JE. Management of medicines in chronic illness: views of community pharmacists in New South Wales. Journal of Pharmacy Practice and Research. 2009; 39(3): 207-10.
36. Kemp A, Preen DB, Glover J, Semmens J, Roughead EE. How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries. Aust Health Rev 2011; 35(3): 341-9. doi:10.1071/AH10906
37. Australian Government. International Pharmaceutical Price Differences. Canberra: Australian Productivity Commission; 2001.
38. Donovan J. The benefits of the Pharmaceutical Benefits Scheme to the Australian community and the impact of increased copayments. Health Issues. 2002; 71: 17-20.
39. Atella V, Schafheutle E, Noyce P, Hassell K. Affordability of medicines and patient's cost reduction behaviours: Empirical evidence based on SUR estimates from Italy and the United Kingdom. Centre for Economic and International StudiesWorking Paper No 712005. Available at ftp://www. ceistorvergata.it/repec/rpaper/No-71-Atella-Hassell-Noyce-Schafheutle.pdf [Verified 9 October 2012].